Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

17.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
17.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

85.5K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
85.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.0K
LTR Retrotransposons03:08

LTR Retrotransposons

19.3K
LTR retrotransposons are class I transposable elements with long terminal repeats flanking an internal coding region. These elements are less abundant in mammals compared to other class I transposable elements. About 8 percent of human genomic DNA comprises LTR retrotransposons. Some of the common examples of LTR retrotransposons are Ty elements in yeast and Copia elements in Drosophila.
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
19.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OX40 transcriptomic expression and its association with immune checkpoints and clinical outcomes.

Therapeutic advances in medical oncology·2026
Same author

Job resignation between cancer diagnosis and surgery in patients with gastric and esophageal cancer: a multi-institutional cross-sectional study.

International journal of clinical oncology·2026
Same author

GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.

Molecular cancer therapeutics·2026
Same author

Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors.

ImmunoTargets and therapy·2026
Same author

GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.

Molecular cancer therapeutics·2026
Same author

Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy.

NPJ precision oncology·2026

Related Experiment Video

Updated: Jan 7, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.9K

TLR9: A Double-Dealing Toll-Like Receptor.

Megan Nielsen1, Daisuke Nishizaki2, Shumei Kato2

  • 1Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Immunotargets and Therapy
|January 5, 2026
PubMed
Summary

Toll-like receptor 9 (TLR9) plays a dual role in cancer, promoting some tumors while suppressing others. Understanding its complex signaling is key for effective cancer immunotherapy.

Keywords:
NF-κBSTAT3TLR9 agonistcancerimmunotherapyinflammationtoll-like receptor 9

More Related Videos

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1
07:42

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1

Published on: February 28, 2025

866
Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages
12:47

Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages

Published on: November 3, 2014

12.0K

Related Experiment Videos

Last Updated: Jan 7, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.9K
Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1
07:42

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1

Published on: February 28, 2025

866
Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages
12:47

Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages

Published on: November 3, 2014

12.0K

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Toll-like receptors (TLRs) are crucial for innate immunity, with TLR9 detecting pathogen-associated DNA motifs.
  • TLR9 activation initiates signaling pathways (NF-κB, STAT3, MAPK) influencing inflammation and immune responses.
  • Dysregulated TLR9 signaling is implicated in various diseases, including cancer, autoimmunity, and chronic inflammation.

Purpose of the Study:

  • To review the immunological functions and signaling mechanisms of TLR9.
  • To explore the complex and context-dependent roles of TLR9 in cancer pathogenesis.
  • To discuss the therapeutic implications of TLR9 agonists in cancer immunotherapy.

Main Methods:

  • Literature review focusing on TLR9 function, signaling, and cancer biology.
  • Analysis of studies investigating TLR9's dual roles in different cancer types.
  • Examination of clinical applications and challenges of TLR9 agonists (CpG ODNs).

Main Results:

  • TLR9 exhibits context-dependent roles in cancer, acting as both a tumor promoter and suppressor.
  • It drives tumorigenesis in certain cancers (e.g., leukemia, prostate) but suppresses others (e.g., triple-negative breast cancer).
  • TLR9 agonists (CpG ODNs) show promise in cancer immunotherapy, but their dual nature presents therapeutic challenges.

Conclusions:

  • TLR9's "double-dealing" nature in cancer necessitates careful consideration for therapeutic strategies.
  • Understanding tumor-specific TLR9 signaling is vital for optimizing cancer immunotherapy outcomes.
  • Further research is needed to overcome challenges related to TLR9's context-dependent effects and ensure treatment safety.